Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: Relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes

Diabetes Research and Clinical Practice

Volumn 61, Issue 2, 2003, Pages 133-136

  Santos, Katia G ^a   Tschiedel, Balduino ^b   Schneider, João ^b   Souto, Katia ^b   Roisenberg, Israel ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Grupo Hospitalar Conceicao   (Brazil)

Author keywords

Diabetic retinopathy; Polymorphisms; Type 2 diabetes mellitus

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALDEHYDE REDUCTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY;

EID: 0041386370     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00112-8     Document Type: Article

References (15)

1. Diabetic retinopathy. Diabetes Care. 23:(Suppl. 1):2000;S73-S76.
2. Newfield R.S., Polak M., Marchase R., Czernichow P. Epidemiology and genetics of diabetic complications. Diabetologia. 40:(Suppl. 3):1997;B62-B64.
3. den Enden M.K.V., Nyengaard J.R., Ostrow E., Burgan J.H., Williamson J.R. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism: implications for diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 36:1995;1675-1685.
4. Kao Y.L., Donaghue K., Chan A., Knight J., Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes. 48:1999;1338-1340.
5. Demaine A., Cross D., Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest. Ophthalmol. Vis. Sci. 41:2000;4064-4068.
6. Margaglione M., Capucci G., d'Addedda M., et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler. Thromb. Vasc. Biol. 18:1998;562-567.
7. Nagi D.K., McCormack L.J., Mohamed-Ali V., Yudkin J.S., Knowler W.C., Grant P.J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care. 20:1997;1304-1309.
8. Wong T.Y.H., Poon P., Szeto C.C., Chan J.C.N., Li P.K.T. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int. 57:2000;632-638.
9. Broch M., Gutierrez C., Aguilar C., Simon I., Richart C., Vendrell J. Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes-absence of relationship with microangiopathy. Diabetes Care. 21:1998;463.
10. Hoogeveen E.K., Kostense P.J., Eysink P.E.D., et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus - the Hoorn study. Arch. Int. Med. 160:2000;2984-2990.
11. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
12. Neugebauer S., Baba T., Kurokawa K., Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet. 349:1997;473-474.
13. Leske M.C., Wu S.Y., Hyman L., et al. Diabetic retinopathy in a black population: the Barbados Eye study. Ophthalmology. 106:1999;1893-1899.
14. Lahiri D.K., Nurnberger J.I. A rapid non-enzimatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19:1991;5444.
15. Mansfield M.W., Stickland M.H., Grant P.J. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb. Haemost. 74:1995;1032-1034.